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1. Introduction 
The chemical group of lazaroid is a C21-amino-steroid 
complex, devoid of effect on mineralocorticoid and carbohydrate 
metabolism (glucoactive activity)[1]. Contrary, this complex has a 
powerful effect against the pathologic lipoperoxidation occurred on lipid 
membranes. This effect is performed by a steroid-like mechanism but 
devoid of the side effects typical of high-dose steroids as 
methylprednisolone[2]. All the lazaroid members act as "scavengers" of 
oxygen free radicals (ROS) such as hydroxyl radical, lipid peroxides and 
superoxide anion. Along, it inhibits the lipoxygenase and the production 
and release of arachidonic acid. The U-74389G is the most famous 
antioxidant agent of that family. 
The U-74389G implicates over 254 published biomedical 
studies at present. The methodology at least of the 46 (18.11%) of these 
experiments are classified at the tissue ischemia-reperfusion (IR) style. 
The assumption concerned whether the U-74389G can reverse induced 
IR injuries in tissues, surrounding organs or even the patients' health. 
Common affairs were the drug reaction rapidity, the timing of its 
administration and the dosage height. This antioxidant agent may be 
proved more beneficial than described. So specific matters are always 
hardly met in bibliography. A meta-analysis of 35 published related 
studies yielded a certain numeric efficacy of U-74389G (Table 1). This 
certain biomedical work tested the effect of U-74389G on a rat liver 
model. The U-74389G effect was calculated on mean creatine kinase - MB 
(CK-MB) levels.   
 
2. Materials and methods 
2.1 Animal preparation 
Legal vet licenses were ascribed under the 3693/November 
12, 2010 & 14/January 10, 2012 decisions by the local Prefecture in 
which the acknowledged Co. Inc SA belongs. All the consumed and non 
substances, settings and equipment were offered by that Co. at Pikermi - 
Attiki. The Albino female Wistar rats were managed by the precicted 
humanistic care. Ad libitum diet accompanied the 7 days pre-
experimental normal housing in laboratory. Prenarcosis engaged the 
nonstop intra-experimental care including general anesthesia[3], oxygen 
supply, electrocardiogram and acidometry. Post-experimental 
euthanasia excluded awakening and preservation of the animals. The 
rats were successively delivered to four experimental groups; each one 
containing 10 animals. Thus, the following protocol of IR was performed: 
The ischemia stage of 45 min preceded and was common at all groups. 
However, it was followed by reperfusion for: 60 min for group A; 120 
min for group B; 60 min with immediate U-74389G intravenous (IV) 
administration for group C and 120 min with immediate U-74389G IV 
administration for group D. The dose of U-74389G was assessed at 10 
mg/Kg body mass of animals. Ischemia was induced by laparotomic 
clamping inferior aorta over the renal arteries with forceps for 45 min. 
The clamp removal restored the inferior aorta patency and reperfusion. 
The U-74389G was administered just at initiation of reperfusion; 
through inferior vena cava catheter. The CK-MB levels were assessed at 
60th min of reperfusion for A,C groups and at 120th min of reperfusion 
for B,D groups. The fourty female Wistar albino rats were described with 
mean weight (W): 231.875 g [Standard Deviation (SD): 36.59703 g], with 
minimum W: 165 g and maximum W: 320 g. Rats' W could be perhaps a 
confusing factor, e.g. the more obese rats, the higher CK-MB levels. This 
assumption was also tested. 
2.2 Control groups 
The known preceded ischemia of 45 min for the 20 control 
rats (mW: 252.5 g [SD: 39.31988 g]) was followed by reperfusion.  
Group A: Reperfusion lasting 60 min (10 controls rats) concerned mW: 
243 g [SD: 45.77724 g] and mean CK-MB levels: 299.4 UI/L [SD: 
176.6592 UI/L] (Table 2).         
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Group B: Reperfusion lasting 120 min (10 controls rats) concerned mW: 
262 g [SD: 31.10913 g] and mean CK-MB levels: 315 UI/L [SD: 189.6535 
UI/L] (Table 2).  
Lazaroid (L) group 
The known preceded ischemia of 45 min for the 20 L rats 
(mW: 211.25 g [SD: 17.53755 g] was followed by reperfusion in the 
beginning of which 10 mg U-74389G /kg body W were IV administered.  
Group C: Reperfusion lasting 60 min (10 L rats) concerned mW: 212.5 g 
[SD: 17.83411 g] and mean CK-MB levels: 451.3 UI/L [SD: 54.75207 
UI/L] (Table 2).         
Group D: Reperfusion lasting 120 min (10 L rats) concerned mW: 210 g 
[SD: 18.10463 g] and mean CK-MB levels: 395.9 UI/L [SD: 141.9667 
UI/L] (Table 2). 
2.3 Statistical analysis 
Every weight and CK-MB level group was compared with each 
other by statistical standard t-tests (Table 3). Any significant difference 
among CK-MB levels, was investigated whether owed in any potent 
significant weight one. The application of generalized linear models 
(glm) with dependant variable the CK-MB levels was followed. The 3 
independent variables were the U-74389G or no drug administration, 
the reperfusion time and both variables in combination. Inserting the 
rats weight also as an independent variable at glm analysis, a non 
significant relation resulted in (p=0.0723), so as to further investigation 
was not needed.  
 
3. Results 
The glm resulted in: U-74389G administration kept 
significantly increased the CK-MB levels by 116.4 UI/L [210.9841 UI/L - 
21.81587 UI/L] (p= 0.0172). This finding was in accordance with 
standard t-test (p=0.0124). Reperfusion time kept non-significantly 
increased the CK-MB levels by 19.9 UI/L [-121.707 UI/L - 81.90697 
UI/L] (P= 0.6945), also in accordance with the results of standard t-test 
(p=0.5772). However, U-74389G administration and reperfusion time 
together kept non-significantly increased the CK-MB levels by 53.41818 
UI/L [-5.545847 UI/L - 112.3822 UI/L] (p= 0.0745). Reviewing the 
above and table 3, the tables 4 and 5 sum up concerning the alteration 
influence of U-74389G versus reperfusion time. 
 
Table 1: The U-74389G influence (+SD) on the levels of some seric variables [3] concerning reperfusion (rep) time 
Variable 1h rep p-value 1.5h rep p-value 2h rep p-value 
interaction of U-
74389G and rep 
p-value 
WBCC +22.99%+12.45% 0.0914 +30.85%+11.14% 0.0045 +38.70%+17.39% 0.0185 +23.45%+6.28% 0.0004 
RBCC   +1.39%+0.71% 0.7161 +0.64%+0.32% 0.8106 -0.10%+0.05% 0.9762 +1.05%+0.53% 0.4911 
Hematocrit +5.58%+3% 0.0852 +4.73%+2.25% 0.0435 +3.89%+3.44% 0.2608 +3.16%+1.33% 0.0196 
Hemoglobin +5.2%+2.8% 0.0925 +3.9%+2.1% 0.0604 +2.7%+3.2% 0.3544 +2.5%+1.3% 0.0423 
MCH +1.77%+0.96% 0.0663 +2.40%+0.57% 0.0001 +3.03%+0.71% 0.0003 1.33%+0.36% 0.0005 
MCV +2.12%+1.16% 0.0663 +2.88%+0.69% 0.0001 +3.64%+0.85% 0.0003 +1.6%+0.43% 0.0005 
MCHC -0.5%+0.74% 0.4820 -0.95%+0.63% 0.1124 -1.4%+1.12% 0.1603 -0.69%+0.37% 0.0655 
RbcDW -6.13%+3.73% 0.0667 -4.96%+2.27% 0.0175 -3.80%+3.07% 0.1383 -2.54%+1.39% 0.679 
Platelet count -17.79%+9.40% 0.0647 -12.83%+5.79% 0.0303 -7.88%+7.83% 0.2939 -6.12%+3.58% 0.0857 
MPV +9.29%+5.07% 0.0663 +12.77%+3.07% 0.0001 +16.25%+3.81% 0.0003 +7.09%+1.91% 0.0005 
Platelet-crit +3.80%+9.87% 0.6373 +9.23%+6.29% 0.1064 +14.66%+9.03% 0.0833 +6.72%+3.73% 0.0712 
PDW +1.1%+0.88% 0.2368 +1.79%+0.76% 0.0314 +2.49%+1.33% 0.0807 +0.96%+0.46% 0.0396 
Glucose -6.41%+3.50% 0.0663 -8.57%+2.06% 0.0001 -10.74%+2.52% 0.0003 -4.76%+1.28% 0.0005 
Urea -8.51%+4.64% 0.0663 -11.35%+2.73% 0.0001 -14.19%+3.32% 0.0003 -6.31%+1.70% 0.0005 
Creatinine -15.96%+8.71% 0.0663 -21.02%+5.06% 0.0001 -26.09%+6.12% 0.0003 -11.69%+3.16% 0.0005 
Uric acid +20.86%+14.44% 0.1614 +15.43%+9.10% 0.0960 +10%+12.11% 0.3946 +4.78%+5.64% 0.3873 
Total protein                -5.48%+2.99% 0.0663 -7.34%+1.76% 0.0000 -9.20%+2.16% 0.0000 -4.08%+1.10% 0.0000 
Albumins -2.70%+1.47% 0.0663 -3.63%+0.87% 0.0001 -4.57%+1.07% 0.0003 -2.02%+0.54% 0.0005 
ALT3 +11.25%+6.19% 0.0686 -8.83%+11.25% 0.4168 -28.92%+24.55% 0.2206 -4.98%+6.77% 0.4527 
AST +33.94%+15.10% 0.0328 +24.97%+14.34% 0.0593 +16%+22.72% 0.4077 +16.23%+8.58% 0.0583 
γGT +19.35%+18.58% 0.2362 +6.82%+14.89% 0.6442 -5.71%+20.10% 0.7809 +1.23%+9% 0.8877 
ALP  +22.66%+12.37% 0.0663 +31.91%+7.69% 0.0001 +41.16%+9.65% 0.0003 +17.75%+4.79% 0.0005 
ACP -112.54%+20.95% 0.0006 -128.45%+14.84% 0.0000 -144.36%+21.62% 0.0000 -74.45%+9.63% 0.0000 
CPK +54.32%+13.75% 0.0012 +35.34%+17.20% 0.0260 +16.37%+30.24% 0.4951 +18.52%+9.44% 0.0770 
CK-MB +40.46%+ 16.70% 0.0147 +31.60%+13.10% 0.0148 +22.75%+ 22.59% 0.2865 +14.50%+8.16 % 0.0745 
LDH +13.56%+7.40% 0.0663 +18.78%+4.52% 0.0001 +24.01%+5.63% 0.0003 +10.43%+2.82% 0.0005 
Sodium   +1.22%+0.66% 0.0707 +0.17%+0.61% 0.7714 -0.87%+1.03% 0.3995 -0.32%+0.36% 0.3693 
Potassium -10.12%+4.8% 0.0579 -2.14%+5.06% 0.6730 +5.83%+6.79% 0.3801 +2.07%+3.03% 0.4853 
Chloride   -0.58%+0.77% 0.4533 -0.97%+0.53% 0.0879 -1.36%+0.76% 0.1113 -0.75%+0.38% 0.0159 
Calcium    0%+1.75% 1 -0.14%+1.10% 0.8782 -0.28%+1.54% 0.8492 +0.14%+0.64% 0.8245 
Phosphorus   -2.23%+5.51% 0.7966 -1.61%+3.32% 0.5789 -1%+4.48% 0.8129 -1.09%+2% 0.5771 
Magnesium +1.33%+3.59% 0.7033 -0.28%+2.75% 0.9171 -1.90%+5.28% 0.7161 +0.36%+4.58% 0.8228 
Amylase -6.28%+3.43% 0.0663 -8.40%+2.02% 0.0001 -10.53%+2.47% 0.0003 -4.67%+1.26% 0.0005 
Progesterone -46.14%+25.19% 0.0663 -58.04%+13.99% 0.0001 -69.94%+16.41% 0.0003 -32.29%+8.73% 0.0005 
Testosterone +40.35%+28.70% 0.1261 +52.17%+28.69% 0.0451 +64%+44.32% 0.1380 +11.18%+17.97% 0.5245 
Mean 2.03%+27.26% 0.2168 0.19%+29.41% 0.1836 -1.63%+33.15% 0.2389 -0.33%+16.23% 0.2016 
 
Table 2: Weight and CK-MB levels and Std. Dev. of groups 
Groups   Variable Mean Std. Dev    
Α Weight 243 g 45.77724 g 
 CK-MB 299.4 UI/L 176.6592 UI/L 
B Weight 262 g 31.10913 g 
 CK-MB 315 UI/L 189.6535 UI/L 
C Weight 212,5 g 17.83411 g 
 CK-MB 451.3 UI/L 54.75207 UI/L 
D Weight 210 g 18.10463 g 
 CK-MB 141.9667 395.9 UI/L UI/L 
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Table 3: Statistical significance of mean values difference for groups (DG) after statistical standard t test application 
DG Variable Difference p-value 
A-B Weight -19 g 0.2423 
 CK-MB -15.6UI/L 0.7558 
Α -C Weight 30.5 g 0.0674 
 CK-MB -151.9 UI/L 0.0113 
Α -D Weight 33 g 0.0503 
 CK-MB -96.5 UI/L 0.2064 
Β -C Weight 49.5 g 0.0019 
 CK-MB -136.3 UI/L 0.0473 
Β -P Weight 52 g 0.0004 
 CK-MB -80.9 UI/L 0.2786 
C-D Weight 2.5 g 0.7043 
CK-MB 55.4 UI/L 0.3009 
 
Table 4: The restore influence of U-74389G versus reperfusion time 
   p-values 
Increase 95% c. in. Reperfusion time t-test glm 
151.9 UI/L 29.02519 UI/L - 274.7748 UI/L 1h 0.0182 0.0113 
116.4 UI/L 21.81587 UI/L - 210.9841 UI/L 1.5h 0.0124 0.0172 
80.9 UI/L -76.49116 UI/L - 238.2912 UI/L 2h 0.2945 0.2786 
-19.9 UI/L -121.707 UI/L - 81.90697 UI/L reperfusion temps 0.6945 0.5772 
-5.545847 53.41818 UI/L UI/L - 112.3822 UI/L interaction - 0.0745  
 
Table 5: The (%) restore influence of U-74389G in connection with reperfusion time. 
Increase +SD Reperfusion time p-values 
40.46 % + 16.70 % 1h 0.0147 
31.60 % +13.10 % 1.5h 0.0148 
22.75 % + 22.59 % 2h 0.2865 
-5.40% + 14.09% reperfusion temps 0.6358 
14.50% + 8.16 % interaction 0.0745 
 
4. Discussion 
The CK-MB levels can be influenced by ischemic cases. 
Gonçalves ES et al[4] noted a significant increase of the CK-MB plasma 
levels after 30 minutes IR in pilot rats treated by ornithin α-
ketoglutarate. Jebeli M et al[5] found significantly elevated the CK-MB 
serum levels in ischemia or myocardial infarction among patients 
presenting either deterioration of the left ventricular function [(FEVG) < 
35%] or acute phase of myocardial infarction (MI), suffered from 
ventricular tachycardia (VT). Sala MF et al[6] estimated more frequently 
by 3.95-fold the peak of CK-MB levels > 300 IU/L in acute phase of MI 
patients suffering from VT. Serruys PW et al[7] noted no case of raised 
CK-MB levels 10 times over the upper normal limit in patients after the 
success of their first percutaneous coronary intervention (PCCI) 
randomly receiving treatment with either fluvastatine 80 mg/kg or 
placebo one, during 3 to 4 years after hospital exit. Savchuk VI et al[8] 
calculated increased the total activity of CK-MB by 57.3+11.7 mE/ml (p < 
0.001) in coronary blood after myocardial ischemia induction via short 
run in dogs. 
Nediani C et al attenuated all the modifications, particularly, 
the neutrophiles infiltration by aminosteroid administration (4 mg/kg) 
in coronary IR of pigs. The 21-lazaroid aminosteroids[9] trap free 
radicals and work as membrane stabilizers. The energy load reduction 
was reversed in the treated group. Myocardial concentration of 
malondialdehyde was raised in all animals after the reperfusion, but this 
effect was significantly marked with aminosteroids treatment. Moreover, 
an increase in infarctions of ascorbic acid contents and a potency to 
reduce the serum peroxidation rate exposed in animals treated than 
untreated ones, indicate an improvement of the antioxidant protection 
induced by administration of aminosteroids. In addition, the serum rates 
of CK-MB isoenzyme suggest the possibility of the aminosteroids to 
attenuate the modifications of the membrane permeability induced by IR 
damage. The aminosteroid treatment is effective in the reduction of 
morphological and biochemical deteriorations which occur in an IR 
myocardium. 
 
4. Conclusion 
U-74389G administration reduced at non-significantly 
increased the CK-MB levels, getting on decline them from significant to 
non-significant level.   
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